Although IL-2 has only been recommended for the treatments of melanoma and renal cancer [57,58], it has been combined with other agents to treat a spectrum of other cancers, including ovarian, breast, gastric, lung, colorectal, and head-and-neck cancers [59–63]. Here, IL2 is linked to melanoma.